mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.

mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q36987718

about

Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play The Role of Autophagy in Hepatocellular Carcinoma Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends Wogonin induces Beclin-1/PI3K and reactive oxygen species-mediated autophagy in human pancreatic cancer cells Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.Tailoring mTOR-based therapy: molecular evidence and clinical challenges.RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus.Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3.Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells.The mTOR pathway in hepatic malignancies.Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition.Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis.Modulation of autophagy for the treatment of liver diseases.UNC51-like kinase 1, autophagic regulator and cancer therapeutic target.Targeting the tumor stroma in hepatocellular carcinoma.ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer.Zebrafish as a Model Organism for the Development of Drugs for Skin Cancer.K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.New insights into 4E-BP1-regulated translation in cancer progression and metastasis.Atg9b Deficiency Suppresses Autophagy and Potentiates Endoplasmic Reticulum Stress-Associated Hepatocyte Apoptosis in Hepatocarcinogenesis.mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.Reprofiling using a zebrafish melanoma model reveals drugs cooperating with targeted therapeutics.Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.Autophagy Modulation in Cancer: Current Knowledge on Action and Therapy.Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity

P2860

Q26764911-6839EA57-DFAC-4D4F-A18D-D75643F81135 Q26777419-B9BE3800-DC90-4D38-A06A-0B9387E0167B Q26830194-2C06C152-DA9E-410B-9739-C8CE8B9D31BE Q28468351-EEDDD4BC-72A8-4151-8F4A-14BD8ABC4E18 Q28546221-ACC40310-A516-4353-ABC9-F8DCE72E641B Q33422744-CD0E8E78-0C61-4316-A831-DD4D64C43573 Q33735754-189D0990-AD34-4B03-9A34-645D273F3DE0 Q33917547-3AC35A40-C1F8-4039-82EC-D32E2BCE01B3 Q34294170-C019EFDF-C1C7-4A41-AE69-B44DDB259C5F Q34479023-A94C847F-1CD5-4F0C-873C-291FCDA0A0A0 Q34986247-005EB964-B6B1-415E-AB5F-D588BA668A4A Q36350128-FAF53E4D-2AAB-4FDF-BE6A-CD20314A0D81 Q36740744-B614AE9E-56B2-4620-97AF-0D343BB4A09C Q36849266-A6DFF90A-7B74-4E29-AF71-B99E562CCAC7 Q36879470-5A0A4EB6-89B5-4999-B26A-28214992AACA Q37024596-965BA1A0-F063-4BE8-BDD2-4E8D4D8F3709 Q37438760-325F8F24-A778-4152-9F09-65BCCBD6338D Q37709404-22A4F9EC-69C3-4530-B146-B774673F8FF2 Q38081396-642B5D6A-03E9-4C30-8839-1B7129EC4435 Q38155511-72543622-277B-4441-A302-7F32F1BBB3A8 Q38174585-5EC5C59E-CAED-4A6F-9263-EBECBB2880BA Q38176862-A8AE2912-624A-4B27-A065-ACCC050BB5D2 Q38205866-2DFD7F6A-1DAC-4BC1-9C36-63EBA3AD3774 Q38261262-63EC274F-3990-4F41-8C07-11772AC0C839 Q38366586-F675588A-6C56-4F49-8D17-D0AE47B2FB00 Q38532510-1C929018-B821-4DF6-A500-F290E3972523 Q38656012-3C240DCC-19E7-4246-933B-9FE701EB1A4F Q38678966-8D49B3B9-21B9-4B5D-AF39-A6141685F3FC Q38995499-16872256-8740-40D6-ACFF-B13D2F90E35F Q39008859-6501761C-4383-4903-A0B3-944122E78D93 Q39181242-8D154B0B-4EFC-4C87-9F9E-02DBC344400B Q39208340-D4DEE0A9-D4B9-4DD1-BEC0-CEB282940A9D Q40948168-DCB9956F-1426-489A-A39E-4EB85BAD1762 Q40980450-55B9E3CA-4864-4620-8BD7-94DB1ED77601 Q41233635-8515ABCF-7436-4777-8CC5-6A49CDEE9506 Q42199220-55885E97-6C08-4D0D-83B4-462CBEEA02A6 Q46392522-1484E513-D8B8-40E8-97C2-CF486C109484 Q48123819-CF70C6EB-4BF4-47E6-841A-972C9F2467A9 Q52592885-93385696-2A3A-4A43-9C87-91B9F5B700C8 Q56892381-333855E5-2476-43DD-A4FB-DC5161E0768E

P2860

mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q36987718

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

mTOR inhibitors synergize on r ...... y in hepatocellular carcinoma.

@en

type

label

mTOR inhibitors synergize on r ...... y in hepatocellular carcinoma.

@en

prefLabel

mTOR inhibitors synergize on r ...... y in hepatocellular carcinoma.

@en

P1433

Q36987718-4AC4212D-C9C5-4042-AC12-9099805F6BD3

P1476

Q36987718-652E12E7-FE25-4C1E-97F2-3305E707CED8

P2093

Q36987718-21B6852E-FEE0-41E4-8A2B-0BC07752540D

Q36987718-449F5FA0-4C8B-4B51-898C-DED30D08CFF5

Q36987718-4F228DE8-2E13-491B-8307-EAF1DE4F9D71

Q36987718-5CF8E326-0746-4A06-9AD4-FBC12B621885

Q36987718-870BDF15-12CB-493F-BCE1-2D213CAAFB8E

Q36987718-984CA697-C6C8-4628-B3E5-4D3CE0D532A9

Q36987718-A017E519-4338-4FB9-8077-327ABEB5456D

Q36987718-A48440A8-C925-4B69-9105-8291E2F4E309

Q36987718-AE212891-706D-4C7C-983B-45D5EAC5B309

Q36987718-D41E58BD-A25A-422E-A84C-A325F322A595

P2860

Q36987718-00EE4BCB-443F-4DDD-9FE4-E9D66B6F5200

Q36987718-028491A2-CF3E-481D-8046-B71B4C735424

Q36987718-062665CB-BF9F-48E1-A92B-E3074DFFC50A

Q36987718-06B55A3C-E244-44CE-92FA-17C5712A229D

Q36987718-0907A34F-D1B2-4970-83F0-54DF5B69073F

Q36987718-0D1562F7-6BC5-4867-8371-D61F08F40A40

Q36987718-0EBBEEFB-EBA3-4D59-B264-2E560A700658

Q36987718-11149110-94C8-4B50-ACF1-4A5C6E449A00

Q36987718-21306E53-AABC-40A7-B49F-810AF08AA2AA

Q36987718-28242251-6939-4AA1-BF48-8AE6C6ED45A0

P304

Q36987718-3053E66E-9B11-4AF9-A3F9-3BED71E5134D

P31

Q36987718-821C40D0-F628-4756-AED6-31C1EE097AEF

P356

Q36987718-65ABDD49-A1A5-4959-A049-B31D591580B0

P407

Q36987718-3F0870C9-5335-4CEC-81C8-5BED51B2E6A7

P433

Q36987718-F0A833BF-4B4E-4B36-B26D-5762BE5B302D

P478

Q36987718-0DE5B4B2-233B-484E-B814-1526B9991419

P50

Q36987718-81D0A891-6AE7-4958-A6B2-B4D1C644A519

Q36987718-C40E203E-EB74-457A-BC5B-F08808C0FB15

Q36987718-EBBD37A0-A98B-4A75-9B75-32C4F430E780

Q36987718-F25CED9C-F421-4F89-9EDD-450ED7821FA6

Q36987718-FFA998F3-40BC-4728-B094-6D2F4DB2E942

P577

Q36987718-1E6635C8-7271-4DD1-826A-BF293E98B47F

P5875

Q36987718-0160B324-8C63-4096-984F-890495B03BEF

P698

Q36987718-4AD3A297-396D-4FC3-9FF4-A2F8973217D4

P921

Q36987718-20FB908C-C2EE-4356-8BB2-EDF9D2F37608

P932

Q36987718-2BB933A4-DE7B-4C73-96CA-DFC52C642FD5

P356

SCITRANSLMED.3003923

P1433

Science Translational Medicine

P1476

mTOR inhibitors synergize on r ...... gy in hepatocellular carcinoma

@en

P2093

Akio Iwanami

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Conner

http://www.w3.org/2001/XMLSchema#string

George Thomas

http://www.w3.org/2001/XMLSchema#string

Hala Elnakat Thomas

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Tanaka

http://www.w3.org/2001/XMLSchema#string

Liu Manway

http://www.w3.org/2001/XMLSchema#string

Paul S Mischel

http://www.w3.org/2001/XMLSchema#string

S Michel Maira

http://www.w3.org/2001/XMLSchema#string

Sara C Kozma

http://www.w3.org/2001/XMLSchema#string

Snorri S Thorgeirsson

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

S6K1 plays a critical role in early adipocyte differentiation

Akt and autophagy cooperate to promote survival of drug-resistant glioma

mTOR: from growth signal integration to cancer, diabetes and ageing

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice

A comparison of normalization methods for high density oligonucleotide array data based on variance and bias

Sorafenib in advanced hepatocellular carcinoma

P304

139ra84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3003923

http://www.w3.org/2001/XMLSchema#string

P407

P433

139

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Carol A. Mercer

Larissa S Carnevalli

Jesper B. Andersen

P577

2012-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224856065

http://www.w3.org/2001/XMLSchema#string

P698

22539746

http://www.w3.org/2001/XMLSchema#string

P921

P932

3703151

http://www.w3.org/2001/XMLSchema#string